Selleckchem
Nivolumab (anti-PD-1)
A2002
Nivolumab
Info: Supplier Page View Product Specs
Browse Similar Products: Anti-PD1 Antibodies
Our research aims at understanding how some CD4 T cells become autoreactive in melanoma patients treated with check point inhibitors. CD4 T cells are usually identified as CD3+ CD4+ cells. In this experiment, we used Nivolumab to detect PD-1 positive CD4 T cells.
Flow Cytometry
PMA/ionomycin/Calcium-stimulated healthy donor's PBMCs
Surface staining with Nivolumab at 1/1000 (20 min in the dark at 4C)
none
Surface staining with anti-CD4 PEDazzle594, anti-CD3 BUV495, etc, and PE-conjugated anti-human IgG4 secondary antibody to detect Nivolumab (20 min in the dark at 4C)
Cells were fixed and permeabilized with a commercial kit to counterstain for cytokines.
Yellow-green laser on Symphony cytometer
Good signal for PD-1 positive cells was obtained.
Gives a good signal. It is recommended to use on PBMCs from checkpoint therapy-treated patients.
It needs a fluorescent secondary antibody.
Good option for PD-1 staining